首页 研究 调查 数据 调研 战略 供需 策略 专项 现状 风险 运营 监测 深度 竞争 发展 专题 评估 动态 规划 咨询 投资 市场 分析 前景 预测 原创 行业 盈利 评价 经营 规模 观点 展望 前瞻 效益 服务 企业 渠道 细分 区域 投机 企业 生产 趋势 格局 销售 技术 状况 经销 环境 财务 风投 供应 产品 产销 商机 项目 能力 新闻
报告检索
您当前的位置:首页 > 战略报告 > 正文

2018-2025 years of market survey report on Chinas pharmaceutical preparations industry

2018-2025 years of market survey report on Chinas pharmaceutical preparations industry

郑重声明

特别声明:以下报告是由亚泰中研公司权威发布,尽可放心购买。

(北京亚泰中研咨询公司):我公司对所有研究报告产品拥有唯一著作权,公司从未通过任何第三方进行代理销售。亚泰中研是中国拥有研究人员数量最多、规模最大、实力最强的咨询研究机构,报告目录与内容未经亚泰中研公司事先书面许可,拒绝任何方式复制、转载。

  本文章共17208字,分3页,当前第1页,快速翻页:123(the following report is coded B011519, issued by the authority of Yatai China Research Corporation.
[text - version]: the price is 6500 yuan (text version).
[electricity sub edition]: the price is 6800 yuan (electronic version).
[Wen Dian = edition]: the price is 7500 yuan (full version).
[writing unit] Beijing Yatai China Research Corporation
The price is 6000 USD.
[publication date]: the latest authoritative publication.
[report]: text analysis data comparison chart
[delivery time]: within 1 working days
[delivery mode: express mail / SF express /
[link] - Liu Yang / Zhang Ke / Liu Dan
[subscribe phone]: 010-57302159 / 13051511061
[Green Channel]: 13051511061 / 15600031156
[report website]: http://www.yzyjbg.net http://www.zgcysddy.com/
Chapter 1: summary of the development of Chinas pharmaceutical preparations industry 24
1.1 definition and classification of pharmaceutical preparations industry 24
1.1.1 industry concept and definition 24
1.1.2 industry main product category 24
1.2 statistical standard for pharmaceutical preparations industry 24
1.2.1 statistics and statistics of pharmaceutical preparations industry 24
1.2.2 statistical methods for pharmaceutical preparations industry 25
1.3 chemical pharmaceutical industry chain analysis 25
1.3.1 chemical pharmaceutical industry chain 25
1.3.2 downstream market analysis of pharmaceutical preparations industry 26
(1) analysis of the development of pharmaceutical circulation industry 26
(2) analysis of the development of drug terminal market 27
(3) downstream industry development impact analysis 27
1.3.3 raw material market analysis for pharmaceutical preparations industry 28
(1) market for chemical raw materials 28
(2) pharmaceutical packaging market 34
(3) upstream industry development impact analysis 40
1.4 analysis of the development environment of the pharmaceutical preparations industry 41
1.4.1 industry policy environment analysis 41
(1) industry supervision department 41
(2) industry regulation policy 41
(3) drug price adjustment 43
(4) guidance catalogue for industrial restructuring (2011 Edition) 44
(5) 2012 edition of national list of essential medicines 44
(6) industry related dynamic assessment and its impact 46
1.4.2 industry economic environment analysis 47
(1) P growth 47
(2) residents income level and medical security expenditure level 48
(3) the impact of macroeconomics on industry 50
1.4.3 industry social environment analysis 50
(1) quality and safety issues 50
(2) regional imbalance 52
(3) the problem of aging population 52
Overview of the environmental impact of 1.4.4 industry development 53
The second chapter: analysis of the development of chemical pharmaceutical industry 54
2.1 analysis of the development of Chinas pharmaceutical products industry 54
2.1.1 analysis of the development characteristics of Chinas chemical pharmaceutical industry 54
2.1.2 chemical pharmaceutical industry management analysis 55
(1) operation efficiency analysis of pharmaceutical preparation industry 55
(2) profitability analysis of pharmaceutical preparation industry 55
(3) operation capacity analysis of pharmaceutical preparation industry 56
(4) analysis of solvency of pharmaceutical products industry 56
(5) analysis of the development capacity of the pharmaceutical preparation industry 57
2.2 analysis of supply and demand balance in pharmaceutical preparations industry 57
2.2.1 analysis of the supply situation of the national pharmaceutical preparations industry 57
(1) analysis of the total output value of the national pharmaceutical preparations industry 57
(2) analysis of finished products in the national pharmaceutical products industry 58
2.2.2 analysis of supply situation of pharmaceutical preparations in various regions in recent three years 58
(1) in the past three years, the total output value of the top 10 regions is analyzed 58
(2) analysis of the top 10 products in recent three years, 59
2.2.3 analysis of demand for national pharmaceutical preparations industry 60
(1) analysis of the sales value of the national pharmaceutical preparations industry 60
(2) sales analysis of the national pharmaceutical products industry 61
2.2.4 analysis of demand for pharmaceutical preparations in various regions in recent three years 62
(1) in the past three years, the top 10 regions of sales output value are analyzed 62
(2) in the past three years, the top 10 regions of sales revenue were analyzed 62
2.2.5 analysis of production and marketing rates of national pharmaceutical preparations industry 63
2.3 import and export analysis of pharmaceutical products industry 64
2.3.1 import and export market for pharmaceutical preparations industry 64
2.3.2 export market analysis of pharmaceutical preparations industry 64
(1) industry export analysis in 2016 65
(2) industry export analysis 66
2.3.3 import market analysis of pharmaceutical preparations industry 67
(1) industry import analysis in 2016 67
(2) industry import analysis 68
The third chapter: market competition analysis of chemical preparation industry 69
3.1 industry overall market competition analysis 69
3.2 industry competition analysis of international market 69
3.2.1 market development of international pharmaceutical preparations 69
(1) market size 69
(2) R & D input 70
(3) development status of major multinational pharmaceutical companies 71
3.2.2 investment layout of MNCs in China market 75
(1) GlaxoSmithKline Co (GlaxoSmithKline) 75
(2) Johnson (Johnson&Johnson) 76
(3) Bayer company (Bayer) 76
(4) AstraZeneca Pharmaceutical Co., Ltd. (AZPC) 77
(5) Roche Pharmaceuticals (RocheGroup) 78
(6) Shi Guibao Bristol-MyersSquibb 79
(7) Pfizer (Pfizer) 80
(8) Novo Nordisk (NovoNordisk) 81
(9) Nuo Hua (NovartisAG) 82
3.2.3 competitive strategy analysis of multinational corporations in China 83
(1) merger and expansion strategy 83
(2) brand building strategy 84
(3) marketing and channel strategy 85
(4) R & D and innovation strategy 85
(5) human resources strategy 86
3.3 domestic market competition analysis 87
3.3.1 domestic chemicals(4) systemic analysis of subtypes of anti infective drugs 100
4.2.2 market analysis of blood and hematopoietic drugs 105
(1) blood and hematopoietic drugs market size 105
(2) blood product and hematopoietic system product structure 106
(3) blood and hematopoietic system subclass analysis 107
4.2.3 cardiovascular drugs clinical medication market analysis 110
(1) the market size of cardiovascular drugs for clinical use 110
(2) product structure of cardiovascular drug clinical use 111
(3) subclinical analysis of cardiovascular drug use 112
4.2.4 respiratory drugs market analysis 117
(1) scale analysis of respiratory drugs market 117
(2) market structure of respiratory drugs market 118
(3) subclass analysis of respiratory system 118
4.2.5 central nervous system drugs market analysis 122
(1) market size analysis of central nervous system drugs 122
(2) central nervous system drug market product mix 122
(3) subclass analysis of central nervous system drugs 123
Market analysis of 4.2.6 antitumor and immunomodulating drugs 128
(1) market size analysis of antitumor and immunomodulatory drugs 128
(2) market structure of antitumor and immunomodulatory drugs 129
(3) analysis of subtypes of antitumor and immunomodulatory drugs 130
4.2.7 market analysis of digestive system and metabolites clinical medication 137
(1) market size analysis of digestive and Metabolic Drugs 137
(2) market structure of digestive and Metabolic Drugs 138
(3) digestive system and metabolite subclass analysis 138
4.2.8 dermatology market analysis 145
(1) market size analysis of dermatology drugs 145
(2) dermatology market structure 146
(3) subcutaneous analysis of skin diseases 147
4.2.9 musculoskeletal system drug market analysis 150
(1) market size analysis of musculoskeletal drugs 150
(2) the product structure of the musculoskeletal system drug market 151
(3) subclass analysis of musculoskeletal system 151
4.2.10 whole body hormone preparations (excluding hormones) market analysis 157
(1) market size analysis of steroid preparations (excluding hormones) 157
(2) the market structure of hormone preparations (excluding hormones) is 158
(3) the whole body uses hormone preparation (excluding hormone) subclass analysis 159
4.2.11 market analysis of genitourinary and hormones 163
(1) market size analysis of genitourinary and hormones 163
(2) product structure of genitourinary and hormones market 164
(3) genitourinary system and hormone subclass analysis 165
4.2.12 sensory system medication market analysis 170
(1) scale analysis of sensory drug use market 170
(2) product structure of sensory drug market 171
(3) subclass analysis of sensory system 171
4.2.13 market analysis of other classes of drugs 173
(1) market analysis of contrast media 173
(2) general nutrition market analysis 175
(3) market analysis of diagnostic radiopharmaceuticals 177
4.3 subdivision analysis of chemical products (by dosage form) 179
4.3.1 injection 179
(1) market analysis of injection subdivision 179
(2) market analysis of main products of injections 186
4.3.2 oral release form 188
(1) tablets 188
(2) capsule 190
4.4 subdivision of chemical products analysis (by innovation level) 191
4.4.1 by innovation 191
4.4.2 new drug market analysis 192
(1) understanding of the protection period of new drugs 192
(2) new drug research and development situation 192
(3) new drug application status 193
(4) the status of new drug registration and approval 194
(5) progress of new drug approval 195
4.4.3 generic drug market analysis 196
(1) global generic drug market size analysis 196
(2) global analysis of key enterprises of generic drugs 199
(3) analysis of Chinas generic drug market size 201
(4) competition status of Chinas generic drug market 202
(5) patent situation of Chinas generic drugs challenge 202
(6) transformation and upgrading of Chinese generic drugs 203
(7) prospects for Chinas generic drug market development 209
4.5 market analysis of pharmaceutical preparations (by drug administration) 210
4.5.1 prescription drug and OTC drug administration system 210
4.5.2 comparison between prescription and OTC drugs sold 210
4.5.3 prescription drug market analysis 210
(1) global prescription drug market size 210
(2) scale analysis of prescription drug market in China 211
(3) forecast of Chinas prescription drug market outlook 212
4.5.4 OTC market analysis 212
(1) global OTC market analysis 213
(2) scale analysis of the OTC market in China 221
(3) competition in the OTC market in China 222
(4) OTC market forecast 223
4.6 market sales of chemical drugs 227
4.6.1 chemical hospital terminal market sales 227
4.6.2 retail sales of chemical preparations 228
4.7 industry main product technology gap with foreign countries 229
4.7.1 main product technology gap with foreign countries 229
4.7.2 the main reason for the gap with foreign products is 229
4.8 industry major product R & D and innovation trend 229
4.8.1 international R & D and innovation trend of pharmaceutical products 229
4.8.2 R & D and innovation trend of chemical products in China 230
The fifth chapter: market analysis of key areas in the chemical pharmaceutical industry 232
5.1 industry overall regional structure analysis 232
General characteristics of 5.1.1 industry regional structure 232
Regional concentration analysis of 5.1.2 industry 235
Analysis of regional distribution characteristics of 5.1.3 industry 237
5.1.4 industry scale index regional distribution analysis 237
5.1.5 industry benefit indicators regional distribution analysis 238
Analysis of regional distribution of enterprises in 5.1.6 industry 239
5.2 analysis and forecast of Jiangsu chemical preparation industry development 240
5.2.1 development scale of Jiangsu chemical preparation industry 240
5.2.2 status change of Jiangsu chemical preparation industry 241
5.2.3 operation status of Jiangsu chemical preparation industry 242
5.2.4 competition situation of Jiangsu chemical preparation industry 242
5.2.5 River5.6.1 development scale of Shanghai chemical preparation industry 256
5.6.2 status change of Shanghai chemical preparation industry 257
5.6.3 operation status of Shanghai chemical preparation industry 258
5.6.4 competition situation of Shanghai chemical preparation industry 259
5.6.5 Shanghai chemical preparation industry development trend forecast 259
The sixth chapter: analysis of production and operation of major pharmaceutical enterprises in 261
6.1 general situation analysis of chemical pharmaceutical preparations enterprises 261
6.1.1 scale of pharmaceutical preparations industry 261
6.1.2 industrial output value of chemical preparation industry 261
6.1.3 pharmaceutical sales industry revenue and profit 262
6.1.4 innovation analysis of major chemical pharmaceutical companies 263
6.2 case analysis of leading pharmaceutical enterprises in 264
6.2.1 operation analysis of Yangzi Pharmaceutical Group Co. Ltd. 264
(1) analysis of enterprise development profile 264
(2) enterprise production and marketing capability analysis 264
(3) profitability analysis of enterprises 265
(4) enterprise operation capability analysis 265
(5) corporate solvency analysis 266
(6) enterprise development capability analysis 266
(7) enterprise product mix and new product trend 267
(8) enterprise sales channel and network 267
(9) analysis of the advantages and disadvantages of business operation 268
(10) analysis of the latest development trend of enterprises 268
6.2.2 operation analysis of Limited by Share Ltd Harbin Pharmaceutical Group 268
(1) analysis of enterprise development profile 268
(2) main economic indicators analysis 270
(3) profitability analysis of enterprises 270
(4) enterprise operation capability analysis 271
(5) corporate solvency analysis 272
(6) enterprise development capability analysis 272
(7) enterprise product mix and new product trend 273
(8) enterprise sales channel and network 275
(9) analysis of the advantages and disadvantages of business operation 276
Operation analysis of 6.2.3 stone medicine group Co., Ltd. 277
(1) analysis of enterprise development profile 277
(2) main economic indicators analysis 278
(3) profitability analysis of enterprises 278
(4) enterprise operation capability analysis 279
(5) corporate solvency analysis 279
(6) enterprise development capability analysis 280
(7) enterprise product mix and new product trend 280
(8) enterprise sales channel and network 281
(9) analysis of the advantages and disadvantages of business operation 281
6.2.4 Northeast Pharmaceutical Group Limited by Share Ltd operation analysis 281
(1) analysis of enterprise development profile 281
(2) main economic indicators analysis 283
(3) profitability analysis of enterprises 284
(4) enterprise operation capability analysis 285
(5) corporate solvency analysis 285
(6) enterprise development capability analysis 285
(7) enterprise product mix and new product trend 286
(8) enterprise sales channel and network 286
(9) analysis of R & D expenditure of enterprises 287
(10) analysis of the advantages and disadvantages of business operation 288
(11) analysis of enterprise investment merger and reorganization 288
(12) analysis of the latest development trend of enterprises 288
6.2.5 operation analysis of North China Pharmaceutical Limited by Share Ltd 289
(1) analysis of enterprise development profile 289
(2) main economic indicators analysis 291
(3) profitability analysis of enterprises 291
(4) enterprise operation capability analysis 292
(5) corporate solvency analysis 293
(6) enterprise development capability analysis 293
(7) enterprise product mix and new product trend 294 本文章更多内容: 1 - 2 - 3 - 下一页>>

2018-2025 years of market survey report on Chinas pharmaceutical preparations industry
订购电话:010-57302178 010-57302159
绿色通道:13051511061 15600031156(24小时服务)

报告价值

  本报告由亚泰中研制作出版,是您全面深入了解该产业发展状况及投资机会的最佳参考工具。亚泰中研是中国领先产业研究与投资咨询机构,经过十多年时间的发展,亚泰中研已经构建了自有调查渠道包括网络、官方数据库、上市公司、调查公司、研究院、政府部门、行业协会、国外权威研究机构等在内的多渠道、多层面的数据来源;建立了包括国际国内上百个行业的千万级的数据库;形成了多种专业分析模型和研究方法;拥有近百名专业的行业分析师咨询师和业内专家。这些都是亚泰中研产品和服务专业性的有效保证。目前亚泰中研业务范围主要覆盖了细分产业研究、产业分析、市场现状、销售价格、前景展望、战略规划、未来预测、市场调查、市场调研、可行性分析与可行性研究等、商业计划书、营销策划、IPO咨询、专项市场解决方案、产业/园区规划、企业发展战略规划、数据库营销服务等以及为满足企业学习和提升经营能力的世界级经营管理智慧,我们已经成为一家多层次、多维度的综合性投资咨询机构。十多年来,亚泰中研已经为数万家包括政府机构、银行、研究所、行业协会、咨询公司、集团公司和各类投资公司在内的单位提供了专业咨询、信息咨询及研究报告、调查报告服务,并得到客户的广泛认可。

报告价值

· 该行业有多大市场规模?发展前景如何?值不值得投资?

· 市场细分和企业定位是否准确?主要客户群在哪里?营销手段有哪些?

· 您与竞争对手企业的差距在哪里?竞争对手的战略意图在哪里?

· 保持领先或者超越对手的战略和战术有哪些?会有哪些优劣势和挑战?

· 该行业的最新变化有哪些?市场有哪些新的发展机遇与投资机会?

· 该行业发展大趋势是什么?您应该如何把握大趋势并从中获得商业利润?

· 该行业内的成功案例、准入门槛、发展瓶颈、赢利模式、退出机制……

· 进入该行业需要了解哪些信息风险?原材料压力、政策和体制风险分析 ?

· 国内市前景预测,国际市前景预测、行业存在问题及对策解决?

数据支持

· 权威数据:国家统计局、国家信息中心、国家税务总局、国家工商总局、国务院发展研究中心、国家海关总署、全国商业信息中心、商务部研究院、清华大学图书馆、国家图书馆、全国200多个行业协会、行业研究所、海外产业研究机构等上万种专业信息来源。

· 亚泰中研自主研发数据库:亚泰中研细分行业数据库、亚泰中研上市公司数据库、亚泰中研非上市企业数据库、宏观经济数据库、区域经济数据库、产品产销数据库、产品进出口数据库。

· 最新一手数据:遍布全国32个省市业内专家顾问网络,涉及政府统计部门、统计机构、生产厂商、销售商、下游需求商、地方主管部门以及在华投资机构。在中国,亚泰中研咨询拥有最大的数据搜集网络数据库,在研究项目最多的一线城市设立了办事处,并在超过50多个城市建立了操作地,资料搜集的工作已覆盖200个地区。

研发流程

研发流程定制报告

· 步骤1:设立研究小组,确定研究内容

· 步骤2:市场总量调研

· 步骤3:市场占有率调查

· 步骤4:企业产销量上下游调查

· 步骤5:核实来自各方信息渠道的数据与基础资料整理

· 步骤6:进行数据建模分析研究并起草初步研究框架

· 步骤7:专家访谈、审阅并提出意见与建议

· 步骤8:分析师系统分析并撰写最终最新报告
(对行业盈利点、增长点、机会点、预测点等进行系统分析并完成报告)

· 步骤9:客户反馈跟进与售后服务
(对用户提出的有关问题给予免费解答;了解客户反馈,并就有关问题进行深入调查和项目咨询)

热点关注
图说
最新报告
今日推荐